9630 Federal Register / Vol. 87, No. 35 / Tuesday, February 22, 2022 / Notices 

collection requiring burden during the 

testing phase. The type of information to 

be collected and the uses of the 

information is described in the 

supporting statements, found here: 

https://www.reginfo.gov/public/do/ 

PRAViewDocument?ref_nbr=201707- 

0970-005. 

Respondents: (1) Program 

Administrators, (2) Program Staff, and 

(3) Program Clients. 

ANNUAL BURDEN ESTIMATES

[TANF, CW, EHS/HS] 

Instrument 

Number of 

respondents 

(TANF, CW, 

EHS/HS) (total 

over request 

period) 

Number of 

responses per 

respondent 

(total over 

request 

period) 

Average 

burden hours 

per response 

(in hours) 

Total burden 

(in hours) 

Annual burden 

(in hours) 

Phase 3: Diagnosis and Design 

Administrator interviews/focus groups ................................. 48 1 1 48 16 

Staff interviews/focus groups ............................................... 400 1 1 400 133 

Client interviews/focus groups ............................................. 400 1 1 400 133 

Client survey ........................................................................ 400 1 0.25 100 33 

Staff Survey ......................................................................... 400 1 0.25 100 33 

Phase 4: Evaluation 

Administrator interviews/focus groups ................................. 96 1 1 96 32 

Staff interviews/focus groups ............................................... 800 1 1 800 267 

Client interviews/focus groups ............................................. 800 1 1 800 267 

Client survey ........................................................................ 12,000 1 0.25 3,000 1,000 

Staff Survey ......................................................................... 1,200 1 0.25 300 100 

Estimated Total Annual Burden 

Hours: 2,014. 

Comments: The Department 

specifically requests comments on (a) 

whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) the quality, utility, 

and clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Consideration will be given 

to comments and suggestions submitted 

within 60 days of this publication. 

Authority: 42 U.S.C. 1310. 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–03669 Filed 2–18–22; 8:45 am] 

BILLING CODE 4184–07–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Detecting Cognitive 

Impairment, Including Dementia, in Primary 

Care and Other Everyday Clinical Settings for 

the General Public and Health Equity, 

Pragmatic Clinical Trials (U01 Clinical Trial 

Required). 

Date: March 29, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Ana Olariu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Boulevard, 

Room 3208, MSC 9529, Bethesda, MD 20892, 

301–496–9223 Ana.Olariu@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; BRAIN Initiative Advanced 

Postdoctoral Career Transition Award to 

Promote Diversity (K99/R00 Independent 

Clinical Trial Not Allowed). 

Date: March 30, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Lataisia Cherie Jones, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, NINDS/NIH, NSC, 6001 Executive 

Boulevard, Suite 3208, Rockville, MD 20852, 

301–496–9223, lataisia.jones@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Diversity K01 & MOSAIC 

Postdoctoral Career Transition Award to 

Promote Diversity (K99/R00 Independent 

Clinical Trial Not Allowed). 

Date: March 31, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Lataisia Cherie Jones, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, NINDS/NIH, NSC, 6001 Executive 

Boulevard, Suite 3208, Rockville, MD 20852, 

301–496–9223, lataisia.jones@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 35 / Tuesday, February 22, 2022 / Notices 9631 

Dated: February 15, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–03667 Filed 2–18–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Secondary Data 

Analysis Applications (R21). 

Date: March 28, 2022. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, National 

Institutes of Health, 6700B Rockledge Drive, 

Suite 3400, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Ashley Fortress, Ph.D., 

Designated Federal Official, Division of 

Extramural Activities, National Eye Institute, 

National Institutes of Health, 6700B 

Rockledge Drive, Ste. 3400, Bethesda, MD 

20892, (301) 451–2020, ashley.fortress@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: February 15, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–03668 Filed 2–18–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Minority Health 

and Health Disparities; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Minority Health and Health Disparities 

Special Emphasis Panel; HIV Health 

Disparity Research in Primary Care Settings. 

Date: March 30, 2022. 

Time: 2:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Gateway Plaza, 7201 Wisconsin Ave., 

Bethesda, MD 20817 (Virtual Meeting). 

Contact Person: Xinli Nan, M.D., Ph.D., 

Scientific Review Officer, Division of 

Scientific Programs, National Institute on 

Minority Health and Health Disparities, 

National Institutes of Health, Gateway 

Building, 7201 Wisconsin Avenue, Bethesda, 

MD 20892, 301–594–7784, Xinli.Nan@

nih.gov. 

Dated: February 16, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–03665 Filed 2–18–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; URGenT: Translational 

Efforts to Advance Gene-based Therapies for 

Ultra-Rare Neurological and Neuromuscular 

Disorders. 

Date: March 9, 2022. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Mirela Milescu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH NSC, 6001 Executive Boulevard, 

Suite 3208, MSC 9529, Bethesda, MD 20892, 

mirela.milescu@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: February 15, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–03666 Filed 2–18–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention 

(CSAP) Drug Testing Advisory Board 

(DTAB) will convene via web 

conference on March 9, 2022, from 

10:00 a.m. ET to 1:00 p.m. ET. 

The board will meet in open-session 

on March 9, 2022, from 10:00 a.m. ET 

to 1:00 p.m. ET, to discuss the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs with 

updates from the Department of 

Transportation, the Nuclear Regulatory 

Commission and the Food and Drug 


lotter on DSK11XQN23PROD with NOTICES1